ARCHIVES

Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

“Confidential and Proprietary” Document Proposes Plan for National Network

February 7, 2014

Proposed Criteria For Establishing Carcinogenicity Listed

November 21, 1975

Full Text Of Saffiotti’s Statement

May 7, 1976

Only 20% of Doctors Advise CRC According To Guidelines

October 29, 2010

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014

NCCS Networker Volume 8 Issue 4, Winter 1994

January 13, 1994